AbCellera Biologics (ABCL) to Release Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCLGet Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCLGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. AbCellera Biologics had a negative return on equity of 12.61% and a negative net margin of 410.47%. The company had revenue of $9.95 million during the quarter, compared to analysts’ expectations of $10.73 million. During the same quarter last year, the business posted ($0.14) EPS. The firm’s revenue for the quarter was down 18.4% compared to the same quarter last year. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Trading Down 4.3 %

Shares of ABCL stock opened at $2.92 on Monday. The company’s fifty day moving average price is $3.21 and its 200-day moving average price is $4.09. The stock has a market cap of $858.64 million, a PE ratio of -5.62 and a beta of 0.39. AbCellera Biologics has a 12 month low of $2.65 and a 12 month high of $7.10.

Analysts Set New Price Targets

Separately, KeyCorp reissued an “overweight” rating and set a $5.00 price objective (down previously from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $14.20.

Check Out Our Latest Stock Analysis on AbCellera Biologics

AbCellera Biologics Company Profile

(Get Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

Read More

Earnings History for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.